AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Yuntongding Capsules
Trial: 33350222
Drug: Flunarizine combined
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine combined with Danqi Soft Capsules
Trial: 35491963
Drug: Acetaminophen 1
RxNorm normalized name: acetaminophen 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 g IV with morphine 0.1 mg/kg
Trial: 35491963
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV with morphine 0.1 mg/kg
Trial: 35589575
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg hepatitis B vaccine at 0-1-6 month
Trial: 35589575
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg hepatitis B vaccine at 0-1-2-6 month
Trial: 35589575
Drug: 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg hepatitis B vaccine at 0-1-2-6 month
Trial: 35026342
Drug: Vunakizumab 40
RxNorm normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vunakizumab 40 mg
Trial: 35026342
Drug: Vunakizumab 80
RxNorm normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vunakizumab 80 mg
Trial: 35026342
Drug: Vunakizumab 160
RxNorm normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vunakizumab 160 mg
Trial: 39332633
Drug: Vunakizumab 240
RxNorm normalized name: Vunakizumab
DrugBank: Vunakizumab (DB15154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vunakizumab 240 mg
Trial: 34216635
Drug: Non-pharmaceutical interventions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical interventions (NPIs) implemented during the Covid-19 pandemic
Trial: 32465366
Drug: Point of
RxNorm normalized name: Precision Point of Care Test Strip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point of Care (POC) management of coagulopathy using ROTEM, PFA 200, Multiplate, and 5% albumin solution
Trial: 35435961
Drug: DEC-C (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC-C (35 mg decitabine and 100 mg cedazuridine)
Trial: 35435961
Drug: IV decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV decitabine (20 mg/m2 once daily for the first 5 days of each 28-day cycle)
Trial: 35228493
Drug: Textured Soybean
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Textured Soybean Protein (40 g in 2 dishes for 4 weeks)
Trial: 32811427
Drug: High-dose rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rabeprazole (20 mg twice daily)
Trial: 32811427
Drug: Standard-dose rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose rabeprazole (20 mg once daily)
Trial: 34487151
Drug: Pradefovir 45
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 45 mg
Trial: 34016045
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam besylate (Group R) - induction dose of 0.2 mg/kg and maintenance dosage of 1.0 mg/kg/h
Trial: 34016045
Drug: Propofol (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (Group P) - induction dose of 1.5–2.0 mg/kg and maintenance dosage of 3.0–6.0 mg/kg/h
Trial: 32386275
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of tomato juice
Trial: 32386275
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of tomato juice
Trial: 35437951
Drug: Almonertinib (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib (110 mg) under fasting conditions
Trial: 35437951
Drug: Almonertinib (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib (110 mg) under fed conditions
Trial: 33012643
Drug: Generic drug
RxNorm normalized name: CELECOXIB 200 mg ORAL CAPSULE [Generic drug]
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic drug approval process video
Trial: 34344706
Drug: OKZ 64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKZ 64 mg every 2 weeks
Trial: 34344706
Drug: OKZ 64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKZ 64 mg every 4 weeks
Trial: 34605045
Drug: BMS-986263 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986263 (90 mg)
Trial: 34605045
Drug: BMS-986263 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986263 (45 mg)
Trial: 35065784
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy (2000 mg peanut protein per day for 134 weeks)
Trial: 34669990
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy
Trial: 32641012
Drug: Daily AIH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily AIH (15, 90s episodes at 10.0% O2 with 60s intervals at 20.9% O2)
Trial: 32641012
Drug: Daily SHAM
RxNorm normalized name: Alberto VO5 Normal With Biotin Daily Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SHAM (15, 90s episodes at 20.9% O2 with 60s intervals at 20.9% O2)
Trial: 32641012
Drug: Daily AIH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily AIH + WALK (60-min walking practice)
Trial: 32641012
Drug: Daily SHAM
RxNorm normalized name: Alberto VO5 Normal With Biotin Daily Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SHAM + WALK (60-min walking practice)
Trial: 32641012
Drug: Daily AIH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily AIH and SHAM interventions
Trial: 34543890
Drug: Prenatal DHA
RxNorm normalized name: Prenatal DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal DHA (400 mg/day)
Trial: 33422811
Drug: Metformin users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin users
Trial: 32803709
Drug: Pre-probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-probiotic group (PreProBG, n = 16; 200 g/day yogurt plus 10 g/day inulin+oligofructose)
Trial: 32803709
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (ProBG, n = 16; 200 g/day yogurt only)
Trial: 32920614
Drug: No irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No irrigation after post preparation (G1)
Trial: 36604812
Drug: ATI-450 50-mg
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-450 50-mg oral tablets twice daily
Trial: 34881361
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (100,000 IU as a bolus dose followed by 20,000 IU per week)
Trial: 33617367
Drug: ACCESS intervention
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ACCESS intervention (two-semester cognitive-behavioral treatment program)
Trial: 34498590
Drug: Chronic anticoagulant
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic anticoagulant therapy
Trial: 37966670
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulant
Trial: 35395697
Drug: DWP16001 (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 (0.2, 0.5, 1.0, 2.0 or 5.0 mg single dose)
Trial: 35395697
Drug: DWP16001 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 (0.1, 0.3, 0.5, 1.0 or 2.0 mg once daily for 15 days)
Trial: 33865494
Drug: 7-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day infusion set replacement
Trial: 33865494
Drug: 4-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-day infusion set replacement
Trial: 34409492
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of tranexamic acid (TXA) at incision, three hours post-operatively, and six hours post-operatively
Trial: 34409492
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tranexamic acid (TXA)
Trial: 34409492
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of tranexamic acid (TXA)
Trial: 34260036
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of magnesium citrate
Trial: 33636823
Drug: G6PD activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G6PD activity cutoff <7.85 U/g hemoglobin (Hb) for males
Trial: 33636823
Drug: G6PD activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G6PD activity cutoff <8.95 U/g Hb for females
Trial: 33725780
Drug: Durvalumab (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (maintenance therapy)
Trial: 33374147
Drug: Capsaicin analogue
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin analogue (Capsiate) 24 mg (two doses of 12 mg each)
Trial: 33682603
Drug: SARS-CoV-2 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccines
Trial: 35992551
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment and regular nursing for advanced cancer patients
Trial: 34851250
Drug: Placebo laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laparoscopic assisted TAP (L‐TAP)
Trial: 34851250
Drug: Active L‐TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active L‐TAP
Trial: 32826442
Drug: Local creams
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local creams (control group)
Trial: 33208640
Drug: Stemless implant
RxNorm normalized name: gentian, stemless, whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stemless implant
Trial: 33208640
Drug: Stemmed implant
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stemmed implant
Trial: 32560734
Drug: Dingkun pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dingkun pill (DKP)
Trial: 34583694
Drug: Individual-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-based oral hygiene intervention
Trial: 35039035
Drug: Recaticimab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recaticimab (75 mg every 4 weeks, 150 mg every 8 weeks, 300 mg every 12 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks, 450 mg every 12 weeks)
Trial: 34496799
Drug: Nifedipine (48-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (48-hour oral treatment)
Trial: 34496799
Drug: Placebo (48-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (48-hour oral treatment)
Trial: 35240576
Drug: Acetaminophen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (20 mg·kg body mass‐1)
Trial: 35791320
Drug: CVnCoV vaccine
RxNorm normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVnCoV vaccine (6 or 12 µg doses)
Trial: 35791320
Drug: CVnCoV vaccine
RxNorm normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVnCoV vaccine (two doses)
Trial: 35791320
Drug: CVnCoV vaccine
RxNorm normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVnCoV vaccine (homologous booster doses)
Trial: 39040887
Drug: CVnCoV vaccine
RxNorm normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVnCoV vaccine
Trial: 35791320
Drug: CVnCoV vaccine
RxNorm normalized name: CVnCoV Vaccine
DrugBank: CVnCoV Vaccine (DB15843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVnCoV vaccine (two 12 µg doses)
Trial: 33822441
Drug: Alcohol (males:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (males: 0.80 g/kg; females: 0.72 g/kg)
Trial: 32380746
Drug: 60 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/d goat cheese naturally enriched in n‐3 PUFA and CLA
Trial: 32380746
Drug: 60 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/d control goat cheese
Trial: 34648533
Drug: Meningococcal B
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal B vaccine (Bexsero, GlaxoSmithKline)
Trial: 33650930
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron plus 8 mg dexamethasone
Trial: 32234902
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus platinum-based chemotherapy
Trial: 35243872
Drug: Intensive-treatment group
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive-treatment group
Trial: 33899216
Drug: Electronic point‐of‐care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic point‐of‐care decision support, combination cardiovascular medications (polypills), pharmacy‐based medication adherence program
Trial: 35889755
Drug: Curcumin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin treatment in DM + I/R rats
Trial: 35889755
Drug: DM (streptozotocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DM (streptozotocin, 65 mg/k, single dose, i.v.)
Trial: 36484188
Drug: Pricking‐cupping therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking‐cupping therapy
Trial: 36484188
Drug: Acupuncture‐cupping therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture‐cupping therapy
Trial: 32933955
Drug: RTS,S/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E vaccine and four courses of SMC SP+AQ
Trial: 32933955
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies vaccine in year 1 and hepatitis A vaccine in years 2 and 3 with four cycles of SMC SP+AQ
Trial: 34476770
Drug: Adjunctive Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Brivaracetam (BRV)
Trial: 34476770
Drug: Adjunctive Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Brivaracetam (BRV) in LEV-naive patients
Trial: 34476770
Drug: Adjunctive Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Brivaracetam (BRV) in patients with prior LEV use and discontinuation due to insufficient efficacy
Trial: 34476770
Drug: Adjunctive Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Brivaracetam (BRV) in patients with prior LEV use and discontinuation due to AEs
Trial: 34476770
Drug: Adjunctive Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Brivaracetam (BRV) with strong enzyme-inducing antiseizure medications (EiASMs)
Trial: 34476770
Drug: Adjunctive Brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Brivaracetam (BRV) with sodium channel blockers (SCBs)
Trial: 33188886
Drug: pecavaptan 30
RxNorm normalized name: Pecavaptan
DrugBank: Pecavaptan (DB16279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pecavaptan 30 mg/d
Trial: 33188886
Drug: pecavaptan or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pecavaptan or diuretics as monotherapy
Trial: 33446347
Drug: Well-being intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well-being intervention derived from Well-Being Therapy (WBT)
Trial: 32757999
Drug: Pericapsular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pericapsular injection of 30 mL of ropivacaine and 12 mg of morphine
Trial: 34843023
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (0.3% and 0.15% HA)
Trial: 34068170
Drug: Cocoa flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanol (450‐500 mg)
Trial: 35199973
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of intravenous morphine
Trial: 33435475
Drug: Gum Arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum Arabic (GA) 20 g daily for 12 weeks
Trial: 33435475
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g pectin)
Trial: 34255069
Drug: Trp-3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trp-3 (3 g)
Trial: 34255069
Drug: Trp-1.5 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trp-1.5 (1.5 g)
Trial: 34344121
Drug: Compound wild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound wild chrysanthemum eye masks
Trial: 35834777
Drug: Active maintenance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active maintenance olaparib (300 mg twice daily)
Trial: 35122549
Drug: Metronidazole adjunctive
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole adjunctive to periodontal surgery
Trial: 35122549
Drug: Placebo adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo adjunctive to periodontal surgery
Trial: 34791813
Drug: DEX 40
RxNorm normalized name: Bidex 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 40 mg on days 1-4 of a 4-week cycle for six cycles
Trial: 34791813
Drug: DEX 40
RxNorm normalized name: Bidex 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 40 mg on days 1-4 of a 4-week cycle for six cycles with ruxolitinib 15 mg BID on days 1-21 of each cycle
Trial: 33077895
Drug: Elamipretide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elamipretide (40 mg per day)
Trial: 36221362
Drug: Hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic sodium lactate infusion
Trial: 32788268
Drug: Initial fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial fasting and intravenous fluids (control)
Trial: 35251940
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus app-based intervention after the active study phase (waitlist control/TAU group)
Trial: 32537847
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg on days 1 and 15 and merestinib 80 mg once daily (QD; 28-day cycle)
Trial: 35138568
Drug: SRP+low‐level laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP+low‐level laser therapy (LLLT) with Nd:YAG laser (group 2)
Trial: 33066856
Drug: Turmacin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmacin 0.5 g
Trial: 33066856
Drug: Turmacin 1
RxNorm normalized name: Turimycin A5
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmacin 1 g
Trial: 33356569
Drug: Multimodal pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pain regimen (pregabalin, celecoxib, acetaminophen, regional block with oxycodone for breakthrough pain)
Trial: 33356569
Drug: Conventional pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pain management (regional block, acetaminophen, oxycodone)
Trial: 35644038
Drug: Family based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family based treatments (FBTs)
Trial: 33010766
Drug: Trochlear resurfacing
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Trochlear resurfacing with HemiCAP® PF Classic implant
Trial: 36175532
Drug: Modified nasopharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified nasopharyngeal oxygen therapy (Group Naso)
Trial: 36175532
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (Group HFNO)
Trial: 33454393
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with routine oral hygiene maintenance instructions (OHMI)
Trial: 33454393
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral hygiene maintenance instructions (OHMI) alone
Trial: 33761206
Drug: ALVAC-HIV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV vaccine regimen (2704 participants)